Move Beyond Traditional Animal Models

Ncardia Leads the Way With iPSC-Derived Platforms

As pioneers in iPSC technology, Ncardia helps you move beyond traditional animal models with innovative, scalable and human-relevant solutions that meet the FDA’s animal testing requirements outlined in the “Roadmap to Reduce Animal Testing in Preclinical Safety Studies.”

What Is the FDA’s “Roadmap to Reduce Animal Testing in Preclinical Safety Studies”?

The FDA’s latest guidance encourages the adoption of New Approach Methodologies (NAMs) as scientifically valid alternatives to animal testing. Read our blog for a full breakdown of the roadmap and its implications for your pipeline.

Innovative Platforms to Reduce Animal Testing in Cardiotoxicity Research

Our human iPSC-derived platforms improve translational relevance, reduce timelines and minimize animal use.

With a broad portfolio of validated assays, high-purity cell types and 3D models like our Ncyte^® vCardiomyocytes, Ncyte^® Heart in a Box™ and upcoming Ncyte^® NHP-C vCardiomyocytes as well as our in-house screening capabilities, Ncardia has everything you need to:

• Reduce animal testing while meeting changing regulatory standards
• Seamlessly integrate human-relevant assays into your workflows
• Model human biology more accurately with scalable, reproducible systems

Generate the data you need to move confidently toward Investigational New Drug (IND) submission.

Ncyte® vCardiomyocytes

Ncyte^® vCardiomyocytes are physiologically relevant, functional ventricular cardiomyocytes (vCMs) built from human iPSC-derived cells and validated across a robust set of key safety pharmacology and cardiotoxicity assays. Perfectly adaptable to all assays’ needs, our vCMs offer a scalable, reproducible, stable and consistent solution for confidently integrating human-relevant cardiac models into your research.

Whether you need our in-house screening services or a reliable cell supply, we provide flexible delivery volumes of up to 10 billion cells per batch to meet your screening campaign’s needs.

Ncyte^® Heart in a Box™

Ncyte^® Heart in a Box™ is the only 100% iPSC-based, completely automatic 3D Cardiac model. It’s high-throughput, optimized for 384-well plate formats and fully compatible with automated screening pipelines — allowing you to capture up to 1,500 data points per day in a complex 3D model.

Our in-house 3D assay capabilities include calcium transient analysis (FDSS), cardiac fibrosis and ischemia-reperfusion studies.

Coming Soon: Ncyte^® NHP-C vCardiomyocytes

Ncyte^® NHP-C vCardiomyocytes are the first-ever non-human primate (NHP)-derived cardiomyocytes available for research use. Made from the cynomolgus macaque, they offer a reliable in vitro alternative to in vivo NHP testing in support of more ethical, translationally aligned preclinical safety research.

Want to be among the first to experience this groundbreaking model?

CardioTox and NeuroTox Services

Featuring the most comprehensive panel of assays designed to fully interrogate any and all liabilities, our CardioTox and NeuroTox services enable both routine screening and comprehensive analysis — delivering a full understanding of your therapeutic and its mechanism of action so you can confidently take the next step.

With our deep knowledge of iPSC platforms and modalities ranging from small molecules to antibodies, we provide a diverse and complex portfolio that works with any study. We also conduct all studies under one roof, ensuring continuity of process.